Searched for
CASH BURN PHARMEASY
PharmEasy to formally discuss IPO plans with its board in second trySources told ET that online pharmacy startup PharmEasy could hit the bourses this year, two years after its previous attempt. The company w...- PharmEasy halves loss to Rs 2,533 crore in FY24, revenue dips 15%Mumbai-based PharmEasy, operated by API Holdings Limited, reported a net loss of Rs 2,533 crore, an improvement from the Rs 5,212 crore los...
- PharmEasy’s FY23 operating revenue up 16% to Rs 6,644 crore; net loss widens 30%PharmEasy’s parent firm API Holdings cut down its advertising and promotional expenses to Rs 235 crore, less than half of what it incurred ...
- 1mg overtakes PharmEasy in market share in top order changeTata 1mg had a 31% market share in September 2023 against 19% in October 2022 while PharmEasy slipped to 15% from about 33% during the same...
- Goldman may convert part-debt into equity in PharmEasyThe online pharmacy is also in talks to restructure debt terms ahead of rights issue; share sale set to open on September 4
- ETtech Explainer: What are down rounds and will they become the norm for Indian startups?A down round is when a privately held firm raises funds at a valuation lower than that ascribed in the previous round.
- Exclusive: PharmEasy plans Rs 2,400-crore rights issue at 90% discount to repay loanMumbai-based epharmacy platform PharmEasy is likely to be valued at $500-600 million compared to the $5.6 billion valuation in 2021
- Global asset manager Janus Henderson cuts PharmEasy valuation further to $2.7 billionAs of March 31, 2023, funds managed by Janus Henderson valued their stake in the startup at $2.7 billion – less than half of the $5.6 billi...
- PharmEasy fails to raise Rs 1,000 crore equity, breaches covenant on Goldman Sachs loanPharmEasy was supposed to raise equity of around Rs 1,000 crore, or about $120 million, linked to its burn rate velocity. It has failed to ...
- Fidelity Investments cuts Meesho's valuation by 10% to $4.4 billionNotably, Fidelity’s funds had valued Meesho at $4.98 billion as of December 2022. Prior to that, as of September 2022, the investor had asc...
- PharmEasy logs first ebitda profit of Rs 14 crore in April, restarts funding talksThe epharmacy held discussions with CDPQ, ADQ; convertible notes are also being discussed amid valuation corrections and markdowns.
- US investor Janus Henderson cuts PharmEasy valuation by half to $2.8 billionThe global investor, which picked a stake in PharmEasy in September 2021, has reduced the valuation of its holding in the firm by half, whi...
- Exclusive: Pine Labs, PharmEasy face markdowns by Neuberger Berman as tech valuations tumbleThe chill in the consumer Internet investment ecosystem and the subsequent cooling down in startups’ growth in India are now being felt thr...
- In 2022, etailers trumped offline stores in smartphone shipments; PharmEasy rules out Thyrocare saleThe calendar year 2022 saw online platforms like Flipkart, Amazon overtake offline retailers in shipments of smartphones from manufacturing...
- Exclusive | Not selling Thyrocare, will cut cash burn: PharmEasy founders to boardPharmEasy’s parent API Holdings has also delayed internal plans for a potential initial public offering (IPO) to 2025, the people privy to ...
- Healthtech startup PharmEasy lays off more employeesThe layoffs were attributed to a variety of factors, including restructuring, macroeconomic headwinds, and the ongoing Russia-Ukraine confl...
- PharmEasy in talks to raise upto $300 million, valuation may drop by halfExisting investors will also put in $70 million, valuation at $2.5-$2.75 versus $5.4 billion of last year’s pre-IPO round. IPO is shelved f...
- Institutional investors oppose Esops; PharmEasy drops IPO, targets Ebitda breakevenThe stock option plans of listed startups such as Zomato and Paytm are facing opposition from institutional investors for a variety of reas...
- PharmEasy delays IPO, targets Ebitda breakeven by next yearThe Mumbai-based firm is also stitching up a private financing round through a rights issue where company founders are expected to invest p...
- PharmEasy may raise $50 million from Fundamentum, othersThe new round comes soon after PharmEasy raised $30 million and will help it build a war chest against rivals like 1mg, Netmeds and others.
Load More
